Sfoglia per AUTORE
SANNA A
Collezione ASL Torino 5

  

Items : 3

Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study. in Haematologica / Haematologica. 2019 Jan;104(1):e4-e8. doi: 10.3324/haematol.2017.183590. Epub 2018 Aug 3.

2019
ASL Torino 5
ASL Torino 4
AO Ordine Mauriziano
AO Cuneo
AOU Città della Salute di Torino

Levis A; Saglio G; Musto P; Bonferroni M; Finelli C; Tassara R; Ferrero D; Cametti G; Poloni A; Balleari E; Sanna A; Allione B; Danise P; Salvi F; Ceccarelli M; Castiglione A; Masiera E; Gioia D; Messa E; Santini V;

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis. in Cancer medicine / Cancer Med. 2019 Dec;8(18):7567-7576. doi: 10.1002/cam4.2638. Epub 2019 Oct 27.

2019
ASL Torino 5
AOU Città della Salute di Torino
ASL Torino 4

Poloni A; Natalie Oliva E; Musto P; Miglino M; Messa E; Masiera E; Lemoli RM; Gioia D; Finelli C; Ferrero D; Pilo F; Danise P; Da Col A; Crisà E; Clavio M; Cilloni D; Cavalleri M; Cavaliere M; Calzamiglia T; Bruzzone M; Angelucci E; Allione B; Salvetti C; Filiberti RA; Balleari E; Salvi F; Sanna A; Scudeletti M; Tassara R; et alii...

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2017 May 10;35(14):1591-1597. doi: 10.1200/JCO.2016.71.3271. Epub 2017 Mar 28.

2017
AOU Alessandria
ASL Torino 5

Fenaux P; Dreyfus F; Sanz GF; Germing U; Sanna A; Pane F; Cametti G; Gaidano G; Ferrero D; Gioia D; Vey N; Rose C; Wattel E; Cheze S; Cony-Makhoul P; Bordessoule D; Guerci-Bresler A; Calabuig M; Ramos F; Bernal T; Roboz GJ; Fensterl J; Steensma DP; Komrokji R; Kotsianidis I; Stamatoullas A; Beyne-Rauzy O; Müller-Thomas C; Götze K; et alii...